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Epigenetic alterations are present not only in cancer
cells but also in non-cancerous tissues. Accumulation
levels of aberrant DNA methylation in non-cancerous
tissues can correlate with risk of cancer development,
especially in chronic inflammation-associated cancers
[1-3]. The close correlation in non-cancerous tissues
was prominent for epigenetic alterations, compared with
genetic alterations, and formed a concept of “epigenetic
field for cancerization (epigenetic field defect)”. In gas-
tric cancers, close correlation between methylation levels
and cancer risk has been demonstrated [4].
As mechanisms for methylation induction in the sto-
mach, infection by Helicobacter pylori (H. pylori), the
major cause of gastric cancers, was implicated in
humans [5], and was demonstrated in Mongolian gerbils
[6]. Especially, a critical role of inflammation triggered
by H. pylori infection, not by high concentrations of
ethanol or salt, was demonstrated, suggesting the impor-
tance of specific chronic inflammation [7]. Gene expres-
sion analysis showed that expression levels of Il1b, Nos,
and Tnf were well correlated with methylation levels
induced.
To dissect molecular mechanisms for induction of epi-
genetic alterations, a mouse colitis model induced by
dextran sulfate sodium (DSS) was used. First, we iso-
lated genes methylated in colon tumors induced by DSS
and azoxymethane, and showed that these genes were
methylated in non-cancerous colonic mucosae, forming
an epigenetic field. Aberrant methylation was induced
even in SCID mice, which lack functional T- and B-lym-
phocytes, and it was shown that lymphocytes are not
essential in methylation induction [8]. By chromatin-
immunoprecipitation-on-Chip analysis of H3K27me3,
aberrant H3K27me3 was shown to be induced by colitis,
and can be carried into cancer tissues and function as a
premark for induction of aberrant DNA methylation [9].
One of the major translations of the epigenetic field
for cancerization is its use as a cancer risk marker. By
searching for CpG islands differentially methylated in
gastric mucosae of gastric cancer patients and healthy
volunteers, both of which had past infection by
H. pylori, we were able to isolate and validate seven dif-
ferentially methylated CpG islands. The new markers
had large areas under the receiver-operating characteris-
tic curves (0.78-0.84) and high odds ratios (12.7-36.0)
even among individuals with past H. pylori infection, com-
pared with two currently available markers (0.60-0.65, 5.0-
5.7) [10]. We are currently conducting a prospective study
to predict patients who suffer from metachronous gastric
cancers among gastric cancer patients treated by endo-
scopic submucosal dissection.
Another translation is prevention of cancers. Several stu-
dies involving viral oncogenes and chemical carcinogens
showed that epigenetic cancer prevention is possible, but
there have been no studies for the usefulness of epigenetic
cancer prevention in chronic inflammation-associated can-
cers. We administered 5-aza-2’-deoxycitidine (5-aza-dC)
to Mongolian gerbils infected with H. pylori after adminis-
tration of N-methyl-N-nitrosourea. It was shown that the
incidence of gastric cancers was suppressed almost to half
of that in gerbils without 5-aza-dC [Niwa, submitted].
These findings vividly show that the epigenetic field
defect has its unique characteristics, such as ease of mea-
surement and reversibility, and harbors a rich chance of
clinical translations.
Competing interests
There are no competing interests in this presentation.
Published: 4 April 2013
Correspondence: tushijim@ncc.go.jp
Division of Epigenomics, National Cancer Center Research Institute, Japan
Ushijima BMC Proceedings 2013, 7(Suppl 2):K22
http://www.biomedcentral.com/1753-6561/7/S2/K22
© 2013 Ushijima; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
References
1. Ushijima T, Hattori N: Molecular Pathways: Involvement of Helicobacter
pylori-Triggered Inflammation in the Formation of an Epigenetic Field
Defect, and Its Usefulness as Cancer Risk and Exposure Markers.
Clin Cancer Res 2012, 18:923-929.
2. Chiba T, Marusawa H, Ushijima T: Inflammation-associated cancer
development in digestive organs: mechanisms and roles for genetic and
epigenetic modulation. Gastroenterology 2012, 143:550-563.
3. Ushijima T: Epigenetic field for cancerization. J Biochem Mol Biol 2007,
40:142-150.
4. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S,
Ichinose M, Sugimura T, Ushijima T, Saito D: Higher methylation levels in
gastric mucosae significantly correlate with higher risk of gastric
cancers. Cancer Epidemiol Biomarkers Prev 2006, 15:2317-2321.
5. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K,
Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T,
Ichinose M, Ushijima T: High levels of aberrant DNA methylation in
Helicobacter pylori-infected gastric mucosae and its possible association
with gastric cancer risk. Clin Cancer Res 2006, 12:989-995.
6. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M,
Tatematsu M, Ushijima T: Inflammatory processes triggered by
Helicobacter pylori infection cause aberrant DNA methylation in gastric
epithelial cells. Cancer Res 2010, 70:1430-1440.
7. Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK, Ushijima T:
Insufficient role of cell proliferation in aberrant DNA methylation
induction and involvement of specific types of inflammation.
Carcinogenesis 2011, 32:35-41.
8. Katsurano M, Niwa T, Yasui Y, Shigematsu Y, Yamashita S, Takeshima H,
Lee MS, Kim YJ, Tanaka T, Ushijima T: Early-stage formation of an
epigenetic field defect in a mouse colitis model, and non-essential roles
of T- and B-cells in DNA methylation induction. Oncogene 2012,
31:342-351.
9. Takeshima H, Ikegami D, Wakabayashi M, Niwa T, Kim YJ, Ushijima T:
Induction of aberrant trimethylation of histone H3 lysine 27 by
inflammation in mouse colonic epithelial cells. Carcinogenesis 2012,
33(12):2384-90.
10. Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T,
Ichinose M, Sugiyama T, Ushijima T: Identification of gastric cancer risk
markers that are informative in individuals with past H. pylori infection.
Gastric Cancer 2012, 15(4):382-8.
doi:10.1186/1753-6561-7-S2-K22
Cite this article as: Ushijima: Epigenetic field for cancerization: its cause
and clinical implications. BMC Proceedings 2013 7(Suppl 2):K22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ushijima BMC Proceedings 2013, 7(Suppl 2):K22
http://www.biomedcentral.com/1753-6561/7/S2/K22
Page 2 of 2
